ORIGINAL ARTICLESSafety of fexofenadine in children treated for seasonal allergic rhinitis
REFERENCES (20)
- et al.
Prevalence of allergic rhinitis in the United States
J Allergy Clin Immunol
(1997) An overview of current pharmacotherapy in perennial rhinitis
J Allergy Clin Immunol
(1995)Sedative effects of antihistamines: safety, performance, learning, and quality of life
Clin Ther
(1997)- et al.
Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis
Ann Allergy Asthma Immunol
(1997) - et al.
Cardiovascular safety of fexofenadine HCl
Am J Cardiol
(1999) - et al.
A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria
J Allergy Clin Immunol
(1999) - et al.
The clinical pharmacology of fexofenadine in children
J Allergy Clin Immunol
(1996) Learning impairment in allergic rhinitis
Allergy Asthma Proc
(1996)- et al.
The relationship of allergies and allergy treatment to school performance and student behavior
Ann Allergy
(1983) Costs of hay fever in the United States in 1990
Ann Allergy
(1994)
There are more references available in the full text version of this article.
Cited by (37)
Safety and tolerability of fexofenadine hydrochloride, 15 and 30 mg, twice daily in children aged 6 months to 2 years with allergic rhinitis
2007, Annals of Allergy, Asthma and ImmunologySafety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old
2007, Annals of Allergy, Asthma and ImmunologyCitation Excerpt :Second-generation antihistamines, such as fexofenadine, are associated with fewer adverse events (AEs) than first-generation antihistamines because of improved histamine1-receptor specificity and reduced capacity to cross the blood-brain barrier.16,17 The safety of fexofenadine has been examined extensively in adults18,19 and school-age children.20-22 However, to date, the safety of fexofenadine in children younger than 6 years has not been established.
Pediatric allergic rhinitis: Treatment
2005, Immunology and Allergy Clinics of North AmericaCurrent concepts and therapeutic strategies forallergic rhinitis in school-age children
2004, Clinical TherapeuticsBioequivalence of 2 Pediatric Formulations of Fexofenadine Hydrochloride Oral Suspension
2023, Clinical Pharmacology in Drug DevelopmentFexofenadine: review of safety, efficacy and unmet needs in children with allergic rhinitis
2021, Allergy, Asthma and Clinical Immunology
This research was supported by a grant from Aventis Pharmaceuticals Inc.
Copyright © 2001 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.